

(English translation)

Minutes of the 2024 Annual General Meeting of Shareholder
Vibhavadi Medical Center Public Company Limited

Time and Place

The Meeting was held on Monday, 29 April 2024 at 1.30 p.m. at the conference room, 9th floors, 4 building, Vibhavadi Hospital, 51/3 Ngamwongwan Rd., Latyao, Jatujak Bangkok 10900.

Opening of the meeting at 1.30 p.m.

Mrs. Bavornphan Rathprasert, Director and Secretary, informed that there were 42 attending the Meeting in person and by proxy 35 shareholders, totaling 77 shareholders attending the Meeting. The total number of shares at the opening of the meeting was 9,695,146,570 shares, equivalent to 71.4138 percent of the shares with voting rights. A quorum was formed in accordance to the Company's Articles of Association.

Mr. Nikom Wairatpanij, Chairman of the Board of Directors, declared the 2024 Annual General Meeting of Shareholders open. In this meeting, the Company had sent the meeting invitation letter via QR CODE, saving 449,328 sheets of paper. This action supports the Emission Reduction Program, which can reduce greenhouse gas emissions by 11,305.09 kgCO₂e, equivalent to planting 1,256 trees.

Mr. Nikom Wairatpanij, Chairman of the Board of Directors, assigned Mrs. Bavornphan Rathprasert, Director and Secretary, suggested the Board of Directors, sub- Committee, Management attending the 2024 Annual General Meeting of Shareholders as follows;

Directors attending the meeting (Directors attending the meeting accounted for 93.33%)

- | | |
|--------------------------------|--|
| 1. Mr. Nikom Wairatpanij | Chairman of the Board of Directors / Independent Director / Audit Committee member / Chairman of the Nomination and Remuneration Committee / Chairman of the Corporate Governance and Sustainability Committee |
| 2. Mr. Chaisith Viriyamettakul | Chairman of Executives Committee / Director / Chairman of the Risk Management and Investment Committee / Nomination and Remuneration Committee member |
| 3. Mr. Sirote Swasdipanich | Chairman of the Audit Committee / Independent Director |
| 4. Mr. Chainarin Sairungsri | Independent Director / Audit Committee member / Corporate Governance and Sustainability Committee member |

- | | |
|---------------------------------|---|
| 5. Mr. Prasert Sriuranpong | Independent Director / Audit Committee member |
| 6. Gen. Boonloet Chuntarapas | Independent Director |
| 7. Mr. Sitthi Panupattanapong | Director / Executive Committee member |
| 8. Mr. Chamnan Chanapai | Director |
| 9. Mr. Pitchaya Somburanasin | Director |
| 10. Mr. Pongpat Patanavanich | Director |
| 11 Mrs. Yada Putthkayon | Director / Executive Committee member / Corporate Governance and Sustainability Committee |
| 12. Ms. Rukkagee Kanjanapitak | Director |
| 13. Mr. Phijit Wiriyamettakul | Director / Managing Director / Executive Committee member / Risk Management and Investment Committee member |
| 14. Mrs. Bavornphan Rathprasert | Director and Secretary / Executive Committee member / Risk Management and Investment Committee member |

Director who did not attend the meeting.

- | | |
|-----------------------|----------|
| 1. Mr. Pramuk Unachak | Director |
|-----------------------|----------|

Attending Managements

- | | |
|-------------------------------|--|
| 1. Lt.Gen. Prompong Peerabool | Vice Chairman of Executive Committee |
| 2. Mr. Chaisit Kupwiwat | Executive Committee member / Risk Management and Investment Committee member / Hospital Director |
| 3. Mr.Yongyut Domesuriya | Chief Financial Officer |
| 4. Mrs. Sasithorn Noragrai | Executive Committee member / Company Secretary |

Auditor

- | | |
|-----------------------------|---|
| 1. Ms. Roongnapha Saengchan | Auditor from Dhammarniti Auditing Co., Ltd. |
|-----------------------------|---|

Shareholders' right protection volunteer

- | | |
|-----------------------------------|----------------------------|
| 1. Ms. Sudsanguan Ngamsuriyaroach | Thai Investors Association |
|-----------------------------------|----------------------------|

The Chairman assigned Mrs. Bavornphan Rathprasert, Director and Secretary, to inform the details of the voting procedures as follows;

1. Each shareholder shall have the number of votes equal to the number of shares held or obtained by proxy.

2. Shareholders attending in person and proxy holders, according to Form A, Form B, and Form C, cannot split their voting rights on each agenda. Voting contrary to these criteria will be considered a spoiled vote and counted as an abstention.

3. For each agenda requiring approval, shareholders in the meeting room who have not yet voted can vote to approve, disagree, or abstain.

4. If shareholders disagree or abstain from voting on any agenda, please raise your hand for the staffs collect your voting slip for further recording.

5. The vote counting will count only the votes of shareholders who vote disagree or abstain from voting on each agenda item. The votes disagree and abstentions will be deducted from the total votes attending at the meeting, and the remaining votes will be considered as approve, as proposed.

6. For every agenda, if shareholders or proxies wish to express opinions or propose questions, please raise your hand.

In this meeting, the Company utilized a shareholder meeting management program, which is a barcode system, and recorded the meeting in video format.

Mrs. Bavornphan Rathprasert, Director and Secretary, informed that the Company has disclosed and invited shareholders propose the agendas and nominate candidates to be elected as directors through the Stock Exchange of Thailand's website and announced on the Company's website on November 3, 2023 to February 14, 2024. It appears that there were no shareholders proposing agenda items or nominating candidates as directors.

Mrs. Bavornphan Rathprasert, Director and Secretary, invited a volunteer from shareholders, who attended the meeting to act as a meeting inspector by overseeing the vote counting with the Company's staff.

Ms. Wawrach Klinjampa, a shareholder, volunteered to participate in the vote counting.

The Chairman conducted the meeting according to the following agenda;

Agenda 1 To consider and adopt the Minutes of the 2023 Annual General Meeting of Shareholders.

The Chairman assigned Mrs. Bavornphan Rathprasert, Director and Secretary, to inform the shareholders about the details of this agenda.

Mrs. Bavornphan Rathprasert, Director and Secretary, informed the Meeting that the minutes of the 2023 Annual General Meeting of Shareholders consist of 22 pages, as received by the shareholders. If any shareholders would like revisions, please raise your hand and notify the staff.

No shareholder raised any questions. The Chairman proposed the Meeting consider the matter for approval.

Resolution The meeting, with unanimous vote of the total votes of all shareholders attending the meeting and having the right to vote, certified the minutes of the 2023 Annual General Meeting of Shareholders. With voting results as follows:

Approved	9,696,296,570	votes	or	100.0000%
Disagreed	-	votes	or	0.0000%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

Agenda 2 To consider and acknowledge the Company's operating results for the year 2023.

The Chairman assigned Mr. Phijit Wiriyametakul, Managing Director, to present the details to the meeting.

Mr. Phijit Wiriyametakul, Managing Director, reported the Company's performance for the year 2023 as follows

Company Group Structure

The Company and its subsidiaries

Private Hospital Business	%	No. of Bed	SSO
Vibhavadi Hospital	100.00%	258	No.
Lanna Hospital	82.57%	330	Yes.
Chiangmai Ram Hospital	46.54%	220	No.
Theppanya 1&2 Hospital	46.54%	170	Yes.
Hariphunchai Ram Hospital	71.59%	220	Yes.
Maesot Ram Hospital	37.13%	100	No.
Ramkhamhaeng Chiangmai Hospital*	45.19%	-	-

Remark *not yet services

Other Business	%
Beauty Design Center Co., Ltd.	46.25%
V Precision Co., Ltd.	70.00%
FERTIVA Co., Ltd.	70.00%
Medica Bangkok Clinic Co., Ltd.	34.88%

Associates

Private Hospital Business	%	No. of Bed	SSO
Vibharam Hospital	33.85%	1,060	Yes.
Bangpo General Hospital	28.57%	100	No.
Khelangnakorn - Ram Hospital	11.84%	103	No.
Chiangrai Ram Hospital	23.34%	59	No.

Other Business	%
Thippayabadin Co., Ltd.	36.50%

Hospital group of Vibha Ram

Private Hospital Business	Status	Location	%	No. of Bed	SSO
Vibharam - Pattanakarn Hospital	Head office	Bangkok	100.00%	150	Yes.
Vibharam - Laemchabang Hospital	Branch	Chonburi	100.00%	100	Yes.
Vibharam - Samutsakhon Hospital	Branch	Samut Sakhon	100.00%	100	Yes.
Sirinart Buengkum Hospital	Temporary close	Bangkok	100.00%	-	No.
Vibharam - Pakkred Hospital	Subsidiary	Nonthaburi	88.46%	100	Yes.
Vibharam (Amata Nakorn) Hospital	Subsidiary	Chonburi	75.11%	137	Yes.
Vibharam - Samutprakan Hospital	Subsidiary	Samut Prakan	99.27%	100	No.
Dr. Panya General Hospital	Subsidiary	Bangkok	50.00%	125	Yes.
Vibharamamata-Cancer Hospital*	Subsidiary	Chonburi	37.56%	10	No.
Synphaet Seriruk Hospital	Associates	Bangkok	16.39%	238	No.

Remark * Vibharam (Amata Nakorn) is holder.

For the location of the hospital and its affiliated hospitals, most are situated in Bangkok, its vicinity, and the eastern region. Meanwhile, the hospitals group of Chiang Mai Ram Medical Business Public Company Limited are located in Chiang Mai, Chiang Rai, Lamphun, Lampang, and Tak.

Performance in 2023

Vibhavadi Hospital provides comprehensive medical services with a total of 12 Excellence Centers. In 2023, Vibhavadi Hospital had 534,456 OPD patients and an IPD bed occupancy rate of 88 percent. Additionally, the Company also provides skin care and beauty services under the name V Design Clinic, hair transplants under the name V Design Hair, and V Precision Clinic, which offers anti-aging services.

In 2023, the Company expanded its operations by establishing Fertiva Co., Ltd. with a registered capital of 40 million baht to operate a fertility treatment center. It is scheduled to open for service in July 2024.

Vibhavadi Hospital, in collaboration with MSD (Thailand) Co., Ltd., the importer of vaccines, opened a vaccination clinic for the public under the name "Jab&Go By Vibhavadi Hospital" at BTS Phaya Thai Station. Two more locations are planned at BTS Phloen Chit Station and MRT Chatuchak Station. Additionally, the hospital opened a Doctor's Choice store, which sells products from the hospital, such as health care products, supplements, skin care products, etc.

Furthermore, Vibhavadi Hospital collaborated with Filtech Enterprise 1994 Public Company Limited to use the Femto Lasik machine for Lasik treatment in 2023, providing treatment with the Femto Lasik machine for 292 eyes.

As for the Vi Plaza building, located within the area of Vibhavadi Hospital, it has opened a fitness center under the name "HEART FITNESS" on the 3rd floor, offering a variety of services such as exercise equipment, children's exercise programs, yoga, dancing, and Pilates.

Cancer center operations, cancer centers have been opened at Vibharam Amata Nakorn Cancer Specialist Hospital and Vibharam Samut Prakan Hospital.

For current projects, the construction of Vibhavadi Hospital, Rama 2 branch, is underway and will be located on Rama 2 Road, Bang Nam Chuet Subdistrict, Mueang Samut Sakhon District, Samut Sakhon Province, with an investment budget of approximately 1,200 million baht and 59 beds. Additionally, the hospital group in the network, Vibharam Hospital-Laem Chabang, is currently constructing an additional building with an investment budget of 690 million baht, expected to be completed in the fourth quarter of 2024.

Performance – Financial in 2023

Revenues	2019	2022	2023
Revenues from medical treatment	6,450.68	8,540.17	8,100.29
Rental and service income	95.21	72.07	73.21
Dividend income	210.43	375.97	360.27
Other income	116.34	77.02	88.15
Total Revenues	6,872.66	9,065.22	8,621.91

Total revenue in 2023 decreased by 4.89 percent from 2022 because, in 2023, the number of COVID-19 patients decreased and there was no distribution of COVID-19 vaccines. However, when comparing the revenue in 2023 with 2019, before the COVID-19 outbreak, total revenue increased by 25.45 percent. The proportion of total revenue in 2023 was as follows: 92 percent from medical treatment, 4 percent from dividends, 2 percent from beauty and anti-aging, 1 percent from rent and services, and 1 percent from other sources.

Profitability Ratios	2019	2022	2023
Gross Profit	1,767.31	2,736.24	2,339.47
Gross Profit Margin	27.00%	31.77%	28.62%
Net Profit	992.80	1,615.24	1,074.51
Net Profit Margin	14.45%	17.82%	12.46%
EBITDA	1,813.73	2,786.57	2,224.19

Profitability Ratios	2019	2022	2023
EBITDA Margin	26.39%	30.74%	25.80%
Earnings per Share	0.0612	0.0987	0.0637

For gross profit and net profit in 2023, there was a decrease from 2022, which is consistent with the decreased revenue. However, when compared to 2019, gross profit and net profit increased in line with the increased revenue.

Total assets in 2023, the amount was 27,813.89 million baht, a decrease of 3,188.88 million baht from 2022. Due to the Company's investment in securities listed on the Stock Exchange of Thailand, whose prices declined, resulting in a reduction in total assets and shareholders' equity in 2023 as well.

For sustainability operations in 2023, Mr. Phijit Wiriyamettakul, Managing Director, assigned Mr. Awirut Niyomdech, Assistant Company Secretary, to present to the meeting for acknowledgment.

Mr. Awirut Niyomdech Assistant Company Secretary, reported to the meeting about the sustainability operations as follows:

1. Environmental Operations

1.1 Green & Clean Hospital Project

- The Company aims to be certified under the Green & Clean Hospital project by planning to increase green spaces and implement recycling waste separation.

1.2 Energy Management

- The Company utilizes 524,467 kWh of solar power, reducing greenhouse gas emissions by 255 tons of CO2 equivalent.

1.3 Waste Management

- The Company campaigns for waste separation before disposal. In 2023, the amount of recyclable waste was 53,787 kilograms, and the daily waste per inpatient decreased from 5.08 kilograms to 4.84 kilograms.

1.4 Greenhouse Gas Management

- The Company measured the greenhouse gas emissions across all three scopes, totaling 12,526 kilograms of CO2 equivalent.

2. Social Operations

2.1 Employee Engagement and Development

- The Company awarded 74 scholarships to employees' children.
- Training is provided to employees, with an average of 20.7 hours of training per person per year.

- The Company conducted an organizational engagement survey, which resulted in a score of 70%

2.2 Human Rights Operations

- The Company conducted a comprehensive human rights audit and implemented measures to compensate those affected by human rights issues. Additionally, a complaint channel was established for human rights violations, with no complaints reported in 2023.

2.3 Access to Medical Services

- The Company established a mobile clinic at the Ha Yaek Lat Phrao BTS station and set up health check-up booths for various communities.

2.4 Occupational Health, Safety, and Environment

- The Company provided health check-ups and flu vaccines (covering four strains) for employees and conducted air quality, lighting, and building inspections, all meeting standard criteria.

2.5 Community Engagement

- The Company organized various activities at the hospital, such as health seminars, training sessions, and blood donation drives, for patients and the interested public to participate in.

3. Governance and Economic Operations

3.1 The Company received an "Excellent" rating in the 2023 Corporate Governance Assessment for Thai Listed Companies by the Thai Institute of Directors Association (IOD).

3.2 The Company was certified as a member of the Thai Private Sector Collective Action Against Corruption, valid for three years (December 30, 2023 - December 30, 2026).

3.3 Quality of Medical and Health Services

- The Company procured efficient and modern medical equipment, such as the 3.0 Tesla MRI machine and the Femto Lasik machine.
- Inpatient rooms in Building 1, Wards 7 and 8, were renovated for greater patient comfort.
- Patient satisfaction was 95% for OPD services and 92% for IPD services.

The Chairman gave the Meeting an opportunity to raise additional questions.

Mr. Kitti Sanitwong Na Ayutthaya, a shareholder, asked how the Company benefited from investing in several other hospitals.

Mr. Chaisit Viriyametakul, the Chairman of the Executive Committee, explained that for the hospital business, starting from construction until opening for service takes about 5 years. Therefore, the Company has chosen to invest by buying shares in companies that are already established in the hospital business. The

Company selects investments in companies that have the potential to operate successfully and pay dividends continuously.

No shareholders raised any further questions. The Chairman proposed to the Meeting acknowledge the Company's operating results for the year 2023.

Resolution The meeting acknowledged the Company's operational performance for the year 2023 as it was proposed.

Agenda 3 To consider and approve financial statements for the year ended December 31, 2023.

The Chairman assigned Mrs. Bavornphan Rathprasert, Director and Secretary, to inform the details of this agenda to the shareholders.

Mrs. Bavornphan Rathprasert, Director and Secretary, informed that the financial statement of Vibhavadi Medical Center Plc. has been audited by the auditor, approved by the Audit Committee, and the Board of Directors. The Company has sent the financial statement to the shareholders in advance, along with the invitation letter, for their acknowledgment and consideration. The details are as follows:

Item	Consolidate (Baht)	Separate (Baht)
Total Assets	27,813,885,226	15,166,091,010
Total Liabilities	11,595,222,534	5,982,170,847
Total equity	16,218,662,692	9,183,920,163
Total Revenues	8,621,910,841	3,496,291,485
Net profit	1,074,505,191	929,981,190
Net profit : owners of the parent	865,124,836	929,981,190
Earnings per share	0.0637	0.0685

The Chairman gave the Meeting an opportunity to raise additional questions.

No shareholder raised any questions. The Chairman proposed that the meeting consider the matter for approval.

Resolution The meeting, with unanimous vote of the total votes of all shareholders attending the meeting and having the right to vote, to approve the financial statements ended December 31, 2023. With voting results as follows:

Approved	9,702,415,113	votes	or	100.0000%
Disagreed	-	votes	or	0.0000%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

Agenda 4 To consider and approve the dividend payment for the year 2023.

The Chairman assigned Mrs. Bavornphan Rathprasert, Director and Secretary, to inform the details of this agenda to the shareholders.

Mrs. Bavornphan Rathprasert, Director and Secretary, informed the Meeting that the Company has the Dividend Payment policy to pay dividends at a rate of not less than 50% of the net profit of the Company after the deduction other legal reserves as annually prescribed by relevant laws and the Company. However, the dividend payment shall be subject to consideration of other factors such as cash flow, liquidity, contractual conditions and limitations, as well as the investment plans of the Company and its affiliates, along with other future necessities and suitability.

Based on the Company's performance and financial statement for the 2023 fiscal year, the Company had a net profit of 1,074,505,191 Baht according to the consolidated financial statements and 929,981,190 Baht according to the separate financial statements. Therefore, the Company propose dividend payment from the operational performance for the 2023 fiscal year to the shareholders in the amount of 13,576,011,474 shares, at rate of 0.050 Baht per share, totaling dividend not exceeding of 678,800,573.70 Baht, representing 72.99% of the net profit according to the separate financial statements, with various factors taken into consideration. The details are as follows:

Details of Dividend Payment	2023 (Baht)	2022 (Baht)
1. Net Profit (Separate)	1,163,432,606.00	901,781,170.00
2. Dividend per share	0.055	0.050
3. Dividend	746,680,631.07	678,793,279.10
4. Dividend ratio	64.18	75.27
5. Par Value	0.10	0.10

In addition, the shares repurchased by the Company will not be entitled to dividends.

In addition, the Company has allocated net profits as a legal reserve not less than ten percent of the paid-up capital in the amount of 149,390,828 Baht.

The Chairman gave the Meeting an opportunity to raise additional questions.

No shareholder raised any questions. The Chairman proposed that the meeting consider the matter for approval.

Resolution The meeting, with unanimous vote of the total votes of all shareholders attending the meeting and having the right to vote, approved dividend payment to shareholders from the operating results for the year 2023 at the rate of Baht 0.050 per share as proposed. In this regard the Company has determined the

Record Date on May 8, 2024, which shareholders have the right to receive dividend and the dividend payment would be paid on May 27, 2024. With voting results as follows:

Approved	9,702,415,113	votes	or	100.0000%
Disagreed	-	votes	or	0.0000%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

Agenda 5 To consider and approve the election of directors to replace those who are retired by rotation.

The Chairman assigned Mrs. Bavornphan Rathprasert, Director and Secretary, to inform the details of this agenda to the shareholders.

The Company published an invitation for shareholders to propose qualified candidates for election as directors on the Company's website and through SET's Setlink from November 3, 2023, to February 14, 2024. The Company received no nominations from any shareholders.

Mrs. Bavornphan Rathprasert, Director and Secretary, informed to the Meeting that the 2024 Annual General Meeting of Shareholders had 5 directors who are retired by rotation as follows;

1. Mr. Chaisith Viriyamettakul Director // Nomination and Remuneration Committee Member / Chairman of Risk Management and Investment Committee member / Chairman of the Executive Committee
2. Mr. Sirote Swasdipanich Director / Chairman of Audit Committee / Independent Director
3. Mr. Prasert Sriuranpong Director / Audit Committee / Independent Director
4. Gen. Boonloet Chuntarapas Director / Independent Director
5. Mr. Sitthi Panupattanapong Director / Executive Director

The Board of directors, excluding the participation of any director having interest therein, has considered the matter with the recommendation of the Nomination and Remuneration Committee which is in line with the nomination guideline set out by the Board of Directors. After considering carefully the profile of each director who is proposed to be elected as the Company's director, the Board of Directors was of view that the proposed directors and independent directors are appropriately qualified without prohibited characteristics under any applicable rules and laws, have knowledge, skills and expertise which will benefit the organization, business ethic, vision, and good attitude toward the Company, and are able to devote their full capability for the interests of the Company and able to provide opinions on an independent basis in accordance with the relevant rules and regulations. The Board of Directors agrees with the Nomination and Remuneration Committee to propose to the 2024 Annual General Meeting of Shareholders to consider the name of all persons to be elected as directors to replace those who retired by rotation at the 2023 Annual General Meeting of Shareholders by voting individually.

The Chairman gave the Meeting an opportunity to raise additional questions.

Ms. Sudsanguan Ngamsuriyaroch, a representative from the Thai Investors Association, asked whether the directors whose terms had expired should leave the meeting.

Mr. Awirut Niyomdech, Assistant Company Secretary, explained that directors whose terms have expired do not need to leave the meeting, as there is no legal requirement preventing them from remaining.

No shareholder raised any questions. The Chairman proposed that the meeting consider the matter for approval.

Resolution The meeting, with majority vote of the total votes of all shareholders attending the meeting and having the right to vote, approved the election of the directors to replace those who are retired by rotation, as follows:

1. Mr. Chaisith Viriyamettakul Director // Nomination and Remuneration Committee Member
/ Chairman of Risk Management and Investment Committee
member / Chairman of the Executive Committee

With voting results as follows:

Approved	9,520,536,929	votes	or	98.1254%
Disagreed	181,878,184	votes	or	1.8746%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

2. Mr. Sirote Swasdipanich Director / Chairman of Audit Committee / Independent Director

With voting results as follows:

Approved	9,702,415,113	votes	or	100.0000%
Disagreed	-	votes	or	0.0000%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

3. Mr. Prasert Sriuranpong Director / Audit Committee / Independent Director

With voting results as follows:

Approved	9,702,415,113	votes	or	100.0000%
Disagreed	-	votes	or	0.0000%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

4. Gen. Boonloet Chuntarapas Director / Independent Director

With voting results as follows:

Approved	9,702,119,413	votes	or	99.9970%
Disagreed	295,700	votes	or	0.0030%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

5. Mr. Sitthi Panupattanapong Director / Executive Director

With voting results as follows:

Approved	9,702,415,113	votes	or	100.0000%
Disagreed	-	votes	or	0.0000%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

Agenda 6 To consider and approve the Directors' and the Committee's remuneration and bonus 2024.

The Chairman assigned Mrs. Bavornphan Rathprasert, Director and Secretary, to inform the details of this agenda to the shareholders.

Mrs. Bavornphan Rathprasert, Director and Secretary, informed to the Meeting that the Nomination and Remuneration Committee has considered remuneration of directors and audit committee member based on the operating results, aligned with industry conditions in the vicinity, and taking into account their respective responsibilities. The details are as follows;

Item	2024 (THB)	2023 (THB)	+/(-)
1. Bonus	5,250,000.00	5,250,000.00	-
2. The Chairman of the Board of Directors	1,560,000.00	1,560,000.00	-
3. Meeting allowance (For the meeting 8 times Meeting allowance 25,000 Baht / person/ time)	3,000,000.00	3,000,000.00	-
4. Audit Committee	960,000.00	960,000.00	-
5. Other benefit	none	none	-
Total	10,770,000.00	10,770,000.00	-
% per total revenues (consolidate)	0.125%	0.119%	-

The Chairman gave the Meeting an opportunity to raise additional questions.

No shareholder raised any questions. The Chairman proposed that the meeting consider the matter for approval.

Resolution The meeting, with unanimous vote of the total votes of all shareholders attending the meeting and having the right to vote, approved the 2024 remuneration and bonus of Board of Directors and Subcommittee of the Company. With the details are as follow:

1. Directors' bonus in the amount of Baht 5,250,000.
2. Remuneration of the Chairman of the Board of Directors in the amount Baht 1,560,000.
3. Meeting allowance in the amount of Baht 3,000,000.
4. Remuneration of Audit Committee in the amount of Baht 960,000.

With voting results as follows;

Approved	9,702,415,113	votes	or	100.0000%
Disagreed	-	votes	or	0.0000%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

Agenda 7 To consider and approve the appointment of auditors and the auditing fees for the year 2024

The Chairman assigned Mr. Sirote Swasdipanich, Chairman of the Audit Committee, to inform the details of this agenda to the shareholders.

Mr. Sirote Swasdipanich, Chairman of the Audit Committee, informed to the Meeting that the Audit Committee has considered to elect auditor for the year 2024 from skill, knowledge abilities and work experience which is benefit to the Company and audit fee has reasonable. the Audit Committee has proposed to the Board of Directors to considered to propose to the Shareholders' meeting appoint Dhammarniti auditing Co., Ltd. as the auditor of the Company for the year 2024. The name, background, year of service as auditor as follows;

1. Mr. Peradate Phongsathainsak	Registration No.	4752
2. Mr. Thanawut Piboonsawat	Registration No.	6699
3. Miss Soraya Tintasuwan	Registration No.	8658
4. Mr. Suwat Maneekanoksakul	Registration No.	8134
5. Miss Potjanarat Siripipat	Registration No.	9012
6. Miss Roongnapha Saengchan	Registration No.	10142
7. Miss Techinee Pornpenpob	Registration No.	10769

Dhammarniti Auditing Co., Ltd. and the seven appointed auditors are approved by The Office of the Securities and Exchange Commission (SEC) and are not relationship and / or do not have any interest in the

Company, Subsidiaries, Executives, Major shareholders or anyone related to the aforementioned persons and does not shareholders of the Company. Therefore, the independent is appropriate for the auditors to give opinions on the Company's financial statements. The appointed auditors from Dharmniti Auditing Co.,Ltd. are responsible for the Company, Subsidiaries and Affiliate companies of which the Company possess the shares.

Auditing fee for year 2024 in the amount of Baht 1,620,000 more than year 2023 in the amount of Baht 60,000, the details are as follows; Therefore, asking the Meeting to consider and approve the appointment of auditors for the year 2024 as proposed.

Audit fees (THB)	2024	2023	Change (+ / -)
1. Review of separate and consolidated financial statements (3 quarters)	690,000.00	660,000.00	30,000
2. Audit the separate and consolidated financial statements.	850,000.00	820,000.00	30,000
3. Audit of the consolidated financial statements of associate companies	80,000.00	80,000.00	-
Total	1,620,000.00	1,560,000.00	60,000

The Chairman gave the Meeting an opportunity to raise additional questions.

No shareholder raised any questions. The Chairman proposed that the meeting consider the matter for approval.

Resolution The meeting, with unanimous vote of the total votes of all shareholders attending the meeting and having the right to vote, approved the appointment of Dharmniti Auditing Co., Ltd. to be the Company's auditors by;

1. Mr. Peradate Phongsathainsak	Registration No.	4752
2. Mr. Thanawut Piboonsawat	Registration No.	6699
3. Miss Soraya Tintasuwan	Registration No.	8658
4. Mr. Suwat Maneekanoksakul	Registration No.	8134
5. Miss Potjanarat Siripipat	Registration No.	9012
6. Miss Roongnapha Saengchan	Registration No.	10142
7. Miss Techinee Pornpenpob	Registration No.	10769

Any one of audit and certify on the Company's financial statements for the year 2024, and auditing fee in the amount of Baht 1,620,000. With voting results as follows:

Approved	9,702,415,113	votes	or	100.0000%
Disagreed	-	votes	or	0.0000%
Abstained	-	votes	or	0.0000%
Voided	-	votes	or	0.0000%

Agenda 8 Other (If any)

The Chairman asked if any shareholders would like to propose any other matters. When no shareholders proposed any other matters, the Chairman gave the shareholders an opportunity to ask questions or express their opinions.

Mr. Amnuay Limsakul, a proxy, asked if there was a chance that the Company and Ramkhamhaeng Hospital Public Company Limited would merge to do business together and what the Company's opinion was on Bangkok Hospital and Samitivej Hospital.

Mr. Chaisit Viriyamettakul, Executive Chairman, explained that the Company had studied the merger with a financial advisor, but due to tax issues, it could not proceed. Regarding the merger with Bangkok Hospital, if the merger were to take place, it could not be done because it would create a monopoly in the market.

Mr. Kitti Sanitwong Na Ayutthaya, a shareholder, asked what the company thought if a capital group from the Middle East invested in the hospital's shares.

Mr. Chaisit Viriyamettakul, the Chairman of Executive Committee, explained that the Company aims to expand its foreign customer base, which is expected to take about 2 years to prepare personnel and facilities. Additionally, the Company is planning to open a fertility treatment center in the third quarter of 2024 and a cancer center at Vibhavadi Hospital, Rama 2 branch. If an investor wants to buy a large number of VIBHA shares, the Company may not be able to sell them due to insufficient shares available for sale.

Mr. Amnuay Limsakul, a proxy, asked two questions: 1. What are the Company's plans to increase revenue in the short and long term? 2. What are the Company's plans for genomic medicine?

Mr. Phijit Wiriyamettakul, Managing Director, explained the answer to the first question regarding the increase in mid-term revenue. Currently, the Company has expanded its products and services, such as hair transplantation, which is expected to grow by 30-40 percent. Additionally, the opening of a fertility treatment clinic, which will start operations in the third quarter, is expected to boost the Company's mid-term revenue. For the long-term, according to the Company's hospital expansion plan, it is anticipated that once the new hospital is completed, it will take approximately 4-5 years to reach full patient capacity, depending on the location of the hospital.

For the second question, V Precision Co., Ltd., a subsidiary, has been operating an anti-aging clinic under the name V Precision Clinic for over 4 years, providing services in anti-aging medicine with modern technology.

Ms. Sudsanguan Ngamsuriyaroch, a representative from the Thai Investors Association, asked that since many hospitals are currently adopting digital technology extensively in their management, how is the Company managing this, and what measures does the Company have in place to prevent cyber-attacks?

Mr. Phijit Wiriyaemattakul, Managing Director, explained that regarding cyber-attack prevention, the Company is in the process of dividing the server into 3 parts to prevent data theft. The first part is real-time data backup, the second part is off-site data backup to prevent data loss in case of disasters affecting the hospital building or fire, and the third part is offline data backup, which involves employees manually inputting data. The Company has invested over 10 million baht in this effort. As for Digital Transformation, it is currently in progress.

Mr. Kittit Sanitwong Na Ayutthaya, a shareholder, asked whether the Company has plans to issue debentures.

Mr. Chaisit Viriyamattakul, the Chairman of Executive Committee, explained that the Company has no plans to issue debentures because it has a good credit rating for borrowing from financial institutions, and the debenture interest rates are higher than the interest rates the Company gets from financial institutions.

When there were no further questions from the shareholders, the chairman thanked the shareholders for attending the meeting and for their questions, which provided the Company with the opportunity to explain and receive various suggestions.

The Meeting adjourned at 2.40 p.m.

(Mr. Nikom Wairatpanij)

Chairman of the Board Director

(Mrs. Bavornphan Rathprasert)

Director and Secretary